These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 16551871)

  • 1. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
    Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
    Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
    Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
    Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
    Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of cytokine-induced killer cells against human lung cancer.
    Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
    Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
    Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
    Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
    Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
    Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
    Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells.
    Zhu XL; Lin ZB
    Acta Pharmacol Sin; 2005 Sep; 26(9):1130-7. PubMed ID: 16115382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.